Medical Council of India Says IAP taking pharma funding is illegal
The Indian Academy of Pediatrics (IAP) has been flouting Medical Council of India regulations on two fronts–one it has been accepting funding from the pharma industry in direct contravention of the rule that no medical association or doctor may accept any freebie or funds from the pharma and healthcare industries. Two it has violated the code of ethics prohibiting endorsement or promotion of any brand.
The annual report of the IAP 2012 giving accounts up to March 31, 2012 showed that it had received over Rs 2.7 crore from the pharmaceutical industry. According to the IAP treasurer, Dr Pravin Mehta’s statement in the report, the academy’s annual expenditure is about Rs 2.77 crore and its income from subscription or membership fees and interest on investment is about Rs 1.77 crore. Thus, industry contributions constitute a significant share of funds for the academy.
However IAP secretary general Dr Sailesh Gupta stated that the general understanding was thatMCI regulation was about individual doctors not accepting funds or gifts and not about associations. “All associations take money from the pharma industry. It is impossible to conduct training for members and other activities and programmes without money from the industry. There is nothing hidden about the funds we take. Or else, why would we put our audited accounts showing the funds taken in the public domain? If the MCI says it is illegal for associations to take money, we will abide by the law,” said Dr Gupta.
MCI secretary Dr Sanjay Shrivastava was categorical that it was illegal for associations of doctors to take funds from companies. “It’s illegal and if we get a complaint, we will take action. We cannot take suo moto action unless the issue is brought to our notice.”
The IAP being a member of the National Technical Advisory Group on Immunisation (NTAGI) is involved in deciding immunisation schedule and selection of vaccines to be included in the NIP. Any vaccine included in the NIP would mean millions of doses of that vaccine being purchased using public funds, a bonanza for the manufacturers.
“The industry funding is not for promoting vaccines to individual paediatricians but to get them approved for the NIP. This is a long term investment for the vaccine industry. For instance, in the case of the pentavalent vaccine, there was opposition to its approval in the NTAGI meeting and then approval was given for its use in Kerala and Tamil Nadu in the state-funded vaccination programmes. IAP was one of the main proponents. If IAP had opposed the move, there would have been a problem. Such considerations do not go into the approval of drugs other than vaccines,” pointed out Dr C M Gulhati, editor of the Monthly Index of Medical Specialties. In fact, Dr Rohit Aggarwal, IAP president 2012, took credit for “convincing the government for inclusion of pentavalent vaccine in NIP” in his message in the annual report. Dr Aggarwal was not only president of IAP but was also the chairperson of the IAP Committee on Immunisation.
In yet another instance of IAP support for a vaccine manufacturer, it flouted MCI regulation against endorsing brands by issuing a public statement (available on its website) endorsing vaccines of Panacea Biotech. In 2011, WHO removed the pentavalent vaccine manufactured by Panacea Biotech from its list of prequalified vaccines due to “serious inadequacies in quality assurance processes”. IAP came to the rescue by stating: “The currently marketed products of M/s Chiron Panacea Vaccines Pvt. Ltd. including the brands, Easyfive, Ecovac4, and EnivacHB are absolutely safe and effective.” It added that even the WHO had stated that there was no evidence of quality or safety defects with batches already distributed.
Similarly, last month, when a doctor’s complaint against GSK’s rotavirus vaccine advertisement was upheld by the Advertising Standards Council of India (ASCI) for claiming that existing practices like hand washing did not help and that vaccination alone could reduce the incidence of rotavirus infection, IAP swung into action. IAP president, Dr Rohit Aggarwal, stated in several media reports that hand washing could not help prevent rotavirus infection “as the transmission is mainly through airborne droplets”. However, the Center for Disease Control and Prevention,Atlanta clearly states on its website page on rotavirus that transmission is mainly by fecal-oral spread as the virus is shed in high concentration in the stool of the infected person. The National Health Service of the UK also states that rotavirus is spread in faeces and is most often spread when someone who is infected does not wash their hand properly after going to toilet. In this context, IAP’s statement against hand washing seems to be misleading and meant to help the vaccine manufacturers.
However, Dr Gupta of IAP insisted that the IAP was careful to ensure that there was no conflict of interest. “All our committee members have to sign conflict of interest statements. We make sure that there is no illegal promotion of products of the companies that give us funds.”
It remains to be seen whether the MCI will step in to set things straight and stop violation of its own regulations.
Pharma industry funds for IAP
|Company||Funds given in lakh Rs|
|Johnson and Johnson||118.4|
Source: IAP Annual Report 2012